Sonrotoclax

Sonrotoclax (BGB-11417) is a potent and selective Bcl-2 inhibitor active against both wild-type and the G101V mutant protein. This investigational small molecule demonstrates antitumor activity in preclinical models of hematological malignancies, supporting its research in leukemia and lymphoma, including in vitro cellular assays and in vivo xenograft studies.

Product Specifications

CAS Number

2383086-06-2

Product Name Alternative

BGB 11417, Bcl-2

Field of Research

Cell Biology

Purity

97.33% (May vary between batches)

Solubility

10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (3.71 mM) ; DMSO:80 mg/mL (89.88 mM)

Smiles

CC (C1=C (C=CC=C1) [C@H]2N (CCC2) C3CC4 (CCN (C5=CC (OC6=CN=C (NC=C7) C7=C6) =C (C=C5) C (NS (=O) (C8=CC ([N+] ([O-]) =O) =C (C=C8) NC[C@@H]9CC[C@@] (O) (CC9) C) =O) =O) CC4) C3) C